;PMID: 7530671
;source_file_857.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:46..134] = [t:46..134]
;2)section:[e:138..205] = [t:138..205]
;3)section:[e:209..261] = [t:209..261]
;4)sentence:[e:265..281] = [t:265..281]
;5)sentence:[e:282..439] = [t:282..439]
;6)sentence:[e:440..561] = [t:440..561]
;7)sentence:[e:562..570] = [t:562..570]
;8)sentence:[e:572..888] = [t:572..888]
;9)sentence:[e:890..898] = [t:890..898]
;10)sentence:[e:899..1033] = [t:899..1033]
;11)sentence:[e:1034..1116] = [t:1034..1116]
;12)sentence:[e:1117..1248] = [t:1117..1248]
;13)sentence:[e:1249..1261] = [t:1249..1261]
;14)sentence:[e:1262..1364] = [t:1262..1364]
;15)sentence:[e:1366..1462] = [t:1366..1462]
;16)section:[e:1466..1510] = [t:1466..1510]

;section 0 Span:0..40
;Gastroenterology. 1995 Feb;108(2):470-6.
(SEC
  (FRAG (NNS:[0..16] Gastroenterology) (IN:[16..17] .) (CD:[18..22] 1995)
        (.:[23..31] Feb;108-LRB-) (CD:[31..32] 2) (-RRB-:[32..33] -RRB-)
        (CD:[33..37] :470) (::[37..38] -) (CD:[38..40] 6.)))

;sentence 1 Span:46..134
;Conformational epitopes on CYP2D6 are recognized by liver/kidney microsomal 
;antibodies.
;[73..79]:cyp450:"CYP2D6"
;[98..133]:substance:"liver/kidney microsomal  antibodies"
(SENT
  (S-HLN
    (NP-SBJ-1
      (NP (JJ:[46..60] Conformational) (NNS:[61..69] epitopes))
      (PP (IN:[70..72] on)
        (NP (NN:[73..79] CYP2D6))))
    (VP (VBP:[80..83] are)
      (VP (VBN:[84..94] recognized)
        (NP-1 (-NONE-:[94..94] *))
        (PP (IN:[95..97] by)
          (NP-LGS
            (NML (NN:[98..103] liver) (SYM:[103..104] /) (NN:[104..110] kidney))
            (JJ:[111..121] microsomal) (NNS:[123..133] antibodies)))))
    (.:[133..134] .)))

;section 2 Span:138..205
;Duclos-Vallee JC, Hajoui O, Yamamoto AM, Jacz-Aigrain E, Alvarez F.
(SEC
  (FRAG (NNP:[138..144] Duclos) (::[144..145] -) (NNP:[145..151] Vallee)
        (NNP:[152..154] JC) (,:[154..155] ,) (NNP:[156..162] Hajoui)
        (NNP:[163..164] O) (NNP:[164..165] ,) (NNP:[166..174] Yamamoto)
        (NNP:[175..177] AM) (,:[177..178] ,) (NNP:[179..183] Jacz)
        (::[183..184] -) (NNP:[184..191] Aigrain) (NNP:[192..193] E)
        (,:[193..194] ,) (NNP:[195..202] Alvarez) (NNP:[203..205] F.)))

;section 3 Span:209..261
;INSERM Unite 347, Hopital de Bicetre, Paris, France.
(SEC
  (FRAG (NNP:[209..215] INSERM) (NNP:[216..221] Unite) (CD:[222..225] 347)
        (,:[225..226] ,) (NNP:[227..234] Hopital) (IN:[235..237] de)
        (NNP:[238..245] Bicetre) (,:[245..246] ,) (NNP:[247..252] Paris)
        (,:[252..253] ,) (NNP:[254..260] France) (.:[260..261] .)))

;sentence 4 Span:265..281
;BACKGROUND/AIMS:
(SENT
  (NP (NN:[265..275] BACKGROUND) (SYM:[275..276] /) (NNS:[276..280] AIMS)
      (::[280..281] :)))

;sentence 5 Span:282..439
;Four linear antigenic sites have been shown on the CYP2D6  molecule that are
;recognized by serum positive for liver/kidney microsomal  antibody (LKM) type
;1.
;[333..339]:cyp450:"CYP2D6"
;[392..438]:substance:"liver/kidney microsomal  antibody (LKM) type 1"
(SENT
  (S
    (NP-SBJ-3
      (NP (CD:[282..286] Four) (JJ:[287..293] linear) (JJ:[294..303] antigenic)
          (NNS:[304..309] sites))
      (SBAR-2 (-NONE-:[309..309] *ICH*)))
    (VP (VBP:[310..314] have)
      (VP (VBN:[315..319] been)
        (VP (VBN:[320..325] shown)
          (NP-3 (-NONE-:[325..325] *))
          (PP (IN:[326..328] on)
            (NP (DT:[329..332] the) (NN:[333..339] CYP2D6)
                (NN:[341..349] molecule)))
          (SBAR-2
            (WHNP-1 (WDT:[350..354] that))
            (S
              (NP-SBJ-1 (-NONE-:[354..354] *T*))
              (VP (VBP:[355..358] are)
                (VP (VBN:[359..369] recognized)
                  (NP-1 (-NONE-:[369..369] *))
                  (PP (IN:[370..372] by)
                    (NP-LGS
                      (NP (NN:[373..378] serum))
                      (ADJP (JJ:[379..387] positive)
                        (PP (IN:[388..391] for)
                          (NP
                            (NML
                              (NML
                                (NML (NN:[392..397] liver) (SYM:[397..398] /)
                                     (NN:[398..404] kidney))
                                (JJ:[405..415] microsomal)
                                 (NN:[417..425] antibody))
                              (NML (-LRB-:[426..427] -LRB-) (NN:[427..430] LKM)
                                   (-RRB-:[430..431] -RRB-)))
                            (NN:[432..436] type) (CD:[437..438] 1)))))))))))))
    (.:[438..439] .)))

;sentence 6 Span:440..561
;The aim of this study was to search for antibodies  against CYP2D6
;conformational antigenic sites in LKM-1-positive sera.
;[480..490]:substance:"antibodies"
;[500..506]:cyp450:"CYP2D6"
;[541..546]:substance:"LKM-1"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[440..443] The) (NN:[444..447] aim))
      (PP (IN:[448..450] of)
        (NP (DT:[451..455] this) (NN:[456..461] study))))
    (VP (VBD:[462..465] was)
      (S-PRP-PRD
        (NP-SBJ (-NONE-:[465..465] *))
        (VP (TO:[466..468] to)
          (VP (VB:[469..475] search)
            (PP-CLR (IN:[476..479] for)
              (NP
                (NP (NNS:[480..490] antibodies))
                (PP (IN:[492..499] against)
                  (NP (NN:[500..506] CYP2D6) (JJ:[507..521] conformational)
                      (JJ:[522..531] antigenic) (NNS:[532..537] sites)))))
            (PP-LOC (IN:[538..540] in)
              (NP
                (ADJP (NN:[541..546] LKM-1) (HYPH:[546..547] -)
                      (JJ:[547..555] positive))
                (NNS:[556..560] sera)))))))
    (.:[560..561] .)))

;sentence 7 Span:562..570
;METHODS:
(SENT
  (NP (NNS:[562..569] METHODS) (::[569..570] :)))

;sentence 8 Span:572..888
;The capacity of four LKM-1-positive sera, before and after absorption with 
;synthetic peptides representing CYP2D6 linear antigenic sites, and rabbit
;sera  against linear antigenic sites between CYP2D6 amino acids 254-271 and
;373-389 to  inhibit the O-demethylation of dextromethorphan by CYP2D6 was
;tested in vitro.
;[593..598]:substance:"LKM-1"
;[658..666]:substance:"peptides"
;[680..686]:cyp450:"CYP2D6"
;[767..773]:cyp450:"CYP2D6"
;[774..785]:substance:"amino acids"
;[786..793]:substance:"254-271"
;[798..805]:substance:"373-389"
;[841..857]:substance:"dextromethorphan"
;[861..867]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[572..575] The) (NN:[576..584] capacity)
        (S-2 (-NONE-:[584..584] *ICH*)))
      (PP (IN:[585..587] of)
        (NP
          (NP
            (NP (CD:[588..592] four)
              (ADJP (NN:[593..598] LKM-1) (HYPH:[598..599] -)
                    (JJ:[599..607] positive))
              (NNS:[608..612] sera))
            (,:[612..613] ,)
            (PP (IN:[614..620] before) (CC:[621..624] and) (IN:[625..630] after)
              (NP
                (NP (NN:[631..641] absorption))
                (PP (IN:[642..646] with)
                  (NP
                    (NP (JJ:[648..657] synthetic) (NNS:[658..666] peptides))
                    (VP (VBG:[667..679] representing)
                      (NP (NN:[680..686] CYP2D6) (JJ:[687..693] linear)
                          (JJ:[694..703] antigenic) (NNS:[704..709] sites))))))))
          (,:[709..710] ,) (CC:[711..714] and)
          (NP
            (NP (NN:[715..721] rabbit) (NNS:[722..726] sera))
            (PP (IN:[728..735] against)
              (NP
                (NP (JJ:[736..742] linear) (JJ:[743..752] antigenic)
                    (NNS:[753..758] sites))
                (PP (IN:[759..766] between)
                  (NP
                    (NP
                      (NP
                        (NML-3 (NN:[767..773] CYP2D6)
                           (JJ:[774..779] amino) (NNS:[780..785] acids))
                        (CD:[786..789] 254))
                      (PP (HYPH:[789..790] -)
                        (NP
                          (NML-3 (-NONE-:[790..790] *P*))
                          (CD:[790..793] 271))))
                    (CC:[794..797] and)
                    (NP
                      (NP
                        (NML-4 (-NONE-:[797..797] *P*))
                        (CD:[798..801] 373))
                      (PP (HYPH:[801..802] -)
                        (NP
                          (NML-4 (-NONE-:[802..802] *P*))
                          (CD:[802..805] 389)))))))))))
      (S-2
        (NP-SBJ (-NONE-:[805..805] *))
        (VP (TO:[806..808] to)
          (VP (VB:[810..817] inhibit)
            (NP
              (NP (DT:[818..821] the) (NN:[822..823] O) (HYPH:[823..824] -)
                  (NN:[824..837] demethylation))
              (PP (IN:[838..840] of)
                (NP (NN:[841..857] dextromethorphan)))
              (PP (IN:[858..860] by)
                (NP (NN:[861..867] CYP2D6))))))))
    (VP (VBD:[868..871] was)
      (VP (VBN:[872..878] tested)
        (NP-1 (-NONE-:[878..878] *))
        (ADVP (FW:[879..881] in) (FW:[882..887] vitro))))
    (.:[887..888] .)))

;sentence 9 Span:890..898
;RESULTS:
(SENT
  (NP (NNS:[890..897] RESULTS) (::[897..898] :)))

;sentence 10 Span:899..1033
;Inhibition of O-demethylation of dextromethorphan was not modified by 
;absorption of antibodies against linear CYP2D6 antigenic sites.
;[932..948]:substance:"dextromethorphan"
;[984..994]:substance:"antibodies"
;[1010..1016]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[899..909] Inhibition))
      (PP (IN:[910..912] of)
        (NP
          (NP (NN:[913..914] O) (HYPH:[914..915] -)
              (NN:[915..928] demethylation))
          (PP (IN:[929..931] of)
            (NP (NN:[932..948] dextromethorphan))))))
    (VP (VBD:[949..952] was) (RB:[953..956] not)
      (VP (VBN:[957..965] modified)
        (NP-1 (-NONE-:[965..965] *))
        (PP (IN:[966..968] by)
          (NP-LGS
            (NP (NN:[970..980] absorption))
            (PP (IN:[981..983] of)
              (NP
                (NP (NNS:[984..994] antibodies))
                (PP (IN:[995..1002] against)
                  (NP (JJ:[1003..1009] linear) (NN:[1010..1016] CYP2D6)
                      (JJ:[1017..1026] antigenic) (NNS:[1027..1032] sites)))))))))
    (.:[1032..1033] .)))

;sentence 11 Span:1034..1116
;In addition,  rabbit sera against two of these sites did not inhibit the
;reaction.
(SENT
  (S
    (PP (IN:[1034..1036] In)
      (NP (NN:[1037..1045] addition)))
    (,:[1045..1046] ,)
    (NP-SBJ
      (NP (NN:[1048..1054] rabbit) (NNS:[1055..1059] sera))
      (PP (IN:[1060..1067] against)
        (NP
          (NP (CD:[1068..1071] two))
          (PP (IN:[1072..1074] of)
            (NP (DT:[1075..1080] these) (NNS:[1081..1086] sites))))))
    (VP (VBD:[1087..1090] did) (RB:[1091..1094] not)
      (VP (VB:[1095..1102] inhibit)
        (NP (DT:[1103..1106] the) (NN:[1107..1115] reaction))))
    (.:[1115..1116] .)))

;sentence 12 Span:1117..1248
;These  results strongly suggest that antibodies against CYP2D6 conformational
;antigenic  sites were present in LKM-1-positive sera.
;[1154..1164]:substance:"antibodies"
;[1173..1179]:cyp450:"CYP2D6"
;[1228..1233]:substance:"LKM-1"
(SENT
  (S
    (NP-SBJ (DT:[1117..1122] These) (NNS:[1124..1131] results))
    (ADVP (RB:[1132..1140] strongly))
    (VP (VBP:[1141..1148] suggest)
      (SBAR (IN:[1149..1153] that)
        (S
          (NP-SBJ
            (NP (NNS:[1154..1164] antibodies))
            (PP (IN:[1165..1172] against)
              (NP (NN:[1173..1179] CYP2D6) (JJ:[1180..1194] conformational)
                  (JJ:[1195..1204] antigenic) (NNS:[1206..1211] sites))))
          (VP (VBD:[1212..1216] were)
            (ADJP-PRD (JJ:[1217..1224] present))
            (PP-LOC (IN:[1225..1227] in)
              (NP
                (ADJP (NN:[1228..1233] LKM-1) (HYPH:[1233..1234] -)
                      (JJ:[1234..1242] positive))
                (NNS:[1243..1247] sera)))))))
    (.:[1247..1248] .)))

;sentence 13 Span:1249..1261
;CONCLUSIONS:
(SENT
  (NP (NNS:[1249..1260] CONCLUSIONS) (::[1260..1261] :)))

;sentence 14 Span:1262..1364
;The autoimmune response  against CYP2D6 is directed against linear and
;conformational antigenic sites.
;[1295..1301]:cyp450:"CYP2D6"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[1262..1265] The) (JJ:[1266..1276] autoimmune)
          (NN:[1277..1285] response))
      (PP (IN:[1287..1294] against)
        (NP (NN:[1295..1301] CYP2D6))))
    (VP (VBZ:[1302..1304] is)
      (VP (VBN:[1305..1313] directed)
        (NP-2 (-NONE-:[1313..1313] *))
        (PP (IN:[1314..1321] against)
          (NP
            (NP (JJ:[1322..1328] linear)
              (NML-1 (-NONE-:[1328..1328] *P*)))
            (CC:[1329..1332] and)
            (NP (JJ:[1333..1347] conformational)
              (NML-1 (JJ:[1348..1357] antigenic) (NNS:[1358..1363] sites)))))))
    (.:[1363..1364] .)))

;sentence 15 Span:1366..1462
;These results strengthen the argument that the LKM-1 response is polyclonal
;and  antigen driven.
;[1413..1418]:substance:"LKM-1"
;[1447..1454]:substance:"antigen"
(SENT
  (S
    (NP-SBJ (DT:[1366..1371] These) (NNS:[1372..1379] results))
    (VP (VBP:[1380..1390] strengthen)
      (NP (DT:[1391..1394] the) (NN:[1395..1403] argument)
        (SBAR (IN:[1404..1408] that)
          (S
            (NP-SBJ (DT:[1409..1412] the) (NN:[1413..1418] LKM-1)
                    (NN:[1419..1427] response))
            (VP (VBZ:[1428..1430] is)
              (ADJP-PRD
                (ADJP (JJ:[1431..1441] polyclonal))
                (CC:[1442..1445] and)
                (ADJP (NN:[1447..1454] antigen) (VBN:[1455..1461] driven))))))))
    (.:[1461..1462] .)))

;section 16 Span:1466..1510
;PMID: 7530671 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1466..1470] PMID) (::[1470..1471] :) (CD:[1472..1479] 7530671)
        (NN:[1480..1481] -LSB-) (NNP:[1481..1487] PubMed) (::[1488..1489] -)
        (NN:[1490..1497] indexed) (IN:[1498..1501] for)
        (NNP:[1502..1510] MEDLINE-RSB-)))
